U
ANIK icon

UBS’s Anika Therapeutics ANIK Stock Holding History

UBS’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Sell
200
-900
-82% -$38.9K ﹤0.01% 9137
2014
Q2 		$51K Sell
1,100
-2,500
-69% -$111K ﹤0.01% 6830
2014
Q1 		$148K Buy
+3,600
New +$134K ﹤0.01% 5528

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

UBS's ANIK Position: Q3 2014 in Review

UBS reduced its Anika Therapeutics (ANIK) stake by 17% in Q3 2014, selling an estimated $338K and leaving 39,231 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

UBS first reported a position in ANIK in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.18M in Q2 2014. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

  • UBS held 39,231 shares of Anika Therapeutics worth $1.44M as of Q3 2014.
  • UBS sold 7,813 Anika Therapeutics shares in Q3 2014, an estimated $338K.
  • Anika Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3221 holding.
  • UBS first reported a position in Anika Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Anika Therapeutics position peaked at $2.18M in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.